These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17969413)

  • 41. [Frequency and stage of relapse after organ-saving combined treatment for urinary bladder cancer].
    Nabruzov SN; Vakhabov OU
    Vopr Onkol; 2008; 54(5):636-8. PubMed ID: 19069481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Bladder cancers in Senegal: epidemiological, clinical and histological features].
    Diao B; Amath T; Fall B; Fall PA; Diémé MJ; Steevy NN; Ndoye AK; Ba M; Mendes V; Diagne BA
    Prog Urol; 2008 Jul; 18(7):445-8. PubMed ID: 18602605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
    Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
    Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
    Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
    Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?
    Volkmer BG; Schnoeller T; Kuefer R; Gust K; Finter F; Hautmann RE
    J Urol; 2009 Dec; 182(6):2632-7. PubMed ID: 19836794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncological outcome after radical cystectomy and orthotopic bladder substitution in women.
    Ali-El-Dein B
    Eur J Surg Oncol; 2009 Mar; 35(3):320-5. PubMed ID: 18434072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiology in the staging of bladder cancer.
    MacVicar D; Husband JE
    Br J Hosp Med; 1994 May 4-17; 51(9):454-8. PubMed ID: 7921502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Primary signet-ring cell carcinoma of the urinary bladder: a case report].
    Fujita M; Otoshi T; Kobayashi K; Fukumoto R; Imamura R; Takada S; Matsumiya K; Fujioka H
    Hinyokika Kiyo; 2009 Sep; 55(9):579-82. PubMed ID: 19827623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
    Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
    J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.
    Liu HB; Kong CZ; Zeng Y; Liu XK; Bi JB; Jiang YJ; Han S
    Urol Oncol; 2009; 27(3):277-83. PubMed ID: 18555709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association.
    Hinotsu S; Akaza H; Miki T; Fujimoto H; Shinohara N; Kikuchi E; Mizutani Y; Koga H; Okajima E; Okuyama A;
    Int J Urol; 2009 Jan; 16(1):64-9. PubMed ID: 19054170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
    Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leiomyosarcoma of the urinary bladder: a case report.
    Gopalakrishnan K; Pai RR; Kini H; Prabhu GG
    Indian J Pathol Microbiol; 2004 Jan; 47(1):58-9. PubMed ID: 15471133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Small cell carcinoma of the urinary bladder: a case report and review of the literature.
    Ismaili N; Ghanem S; Mellas N; Afqir S; Taleb M; Amrani M; Gamra L; Errihani H
    J Cancer Res Ther; 2009; 5(2):133-6. PubMed ID: 19542673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Application of flow-type analyzers in oncology].
    Pinchuk VG; Isakov VL; Mazur LA
    Vopr Onkol; 1983; 29(8):75-83. PubMed ID: 6351430
    [No Abstract]   [Full Text] [Related]  

  • 58. Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis.
    Wright JL; Hotaling J; Porter MP
    J Urol; 2009 Mar; 181(3):1035-9; discussion 1039. PubMed ID: 19150569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
    Ro JY; Shen SS; Lee HI; Hong EK; Lee YH; Cho NH; Jung SJ; Choi YJ; Ayala AG
    Am J Surg Pathol; 2008 May; 32(5):752-7. PubMed ID: 18379419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical outcome of chemoradiotherapy for T1G3 bladder cancer.
    Inoue M; Ishioka J; Fukuda H; Kageyama Y; Saito Y; Higashi Y
    Int J Urol; 2008 Aug; 15(8):747-50. PubMed ID: 18786198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.